Everolimus for Children With Recurrent or Progressive Ependymoma

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

July 14, 2023

Study Completion Date

July 14, 2023

Conditions
Recurrent Childhood Ependymoma
Interventions
DRUG

Everolimus

The recommended dose of Everolimus is 4.5 mg/m2/dose, once daily for up to 2 years, until disease progression or unacceptable toxicity occurs.

Trial Locations (4)

10016

New York University Stephen D. Hassenfeld Children's Center for Cancer & Blood Disorders, New York

75390

UT Southwestern Medical Center / Children's Medical Center, Dallas

77030

Baylor College of Medicine / Texas Children's Hospital, Houston

94305

Lucile Packard Children's Hospital Stanford University, Stanford

All Listed Sponsors
lead

University of Texas Southwestern Medical Center

OTHER

NCT02155920 - Everolimus for Children With Recurrent or Progressive Ependymoma | Biotech Hunter | Biotech Hunter